Novo Nordisk To Slash US List Prices Of Wegovy, Ozempic And Rybelsus by January 2027, Lowers Prices To $675 Across All Doses

Novo Nordisk A/S announced that, effective January 1, 2027, it will reduce the list price wholesale acquisition cost of several semaglutide-based medicines in the United States. The updated WAC for Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus® (semaglutide) tablets 7 mg and 14 mg will be set at $675. This represents price reductions of approximately 50% for Wegovy® and 35% for Ozempic® compared to current list prices. The adjustments apply across all doses of these medicines.

Semaglutide, the active ingredient in Wegovy® and Ozempic®, is a GLP-1 receptor agonist with multiple FDA-approved indications. These include chronic weight management in adults with obesity (Wegovy®), treatment of type 2 diabetes (Ozempic® and Rybelsus®), type 2 diabetes with chronic kidney disease (Ozempic® injection), and reduction of cardiovascular risk in certain patients with obesity or type 2 diabetes.

“Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. “Our actions today answer that call and remove cost barriers so the value of Wegovy® and Ozempic® can be realized by more patients. The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.”

The company stated that the pricing decision reflects its commitment to improving affordability and simplifying access for patients as well as public and private payers navigating the evolving U.S. healthcare landscape. By lowering list prices, Novo Nordisk aims to broaden access to its FDA-approved semaglutide therapies.

The price change does not alter other existing access initiatives, including direct-to-patient or self-pay programs. Novo Nordisk emphasized that the move is part of its ongoing efforts to ensure patients in the U.S. can obtain authentic, FDA-approved treatments in ways that align with their healthcare and financial needs.